Zai Lab Limited (ZLAB)
Nasdaq · Healthcare · Biotechnology
$25.62+5.30%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $2.9B
- 52-week range
- $15.96 – $34.06
- 52-week change
- −26.96%
- EPS (trailing)
- −$1.70
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $460M (+15.33%)
- Net income
- −$176M
- Operating margin
- −49.9%
- Diluted EPS
- −$0.16
- Free cash flow
- −$159M
From the company’s annual report on SEC EDGAR.
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH.
Headquarters: Pudong, China · 1,784 employees · zailaboratory.com